APA (7th ed.) Citation

R, S., L, T., M, I., W, W., CA, B., J, H., . . . J, D. (2020). Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: A randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet (London, England), 396(10252), 684. https://doi.org/10.1016/S0140-6736(20)31541-5

Chicago Style (17th ed.) Citation

R, Savarirayan, et al. "Once-daily, Subcutaneous Vosoritide Therapy in Children with Achondroplasia: A Randomised, Double-blind, Phase 3, Placebo-controlled, Multicentre Trial." Lancet (London, England) 396, no. 10252 (2020): 684. https://doi.org/10.1016/S0140-6736(20)31541-5.

MLA (9th ed.) Citation

R, Savarirayan, et al. "Once-daily, Subcutaneous Vosoritide Therapy in Children with Achondroplasia: A Randomised, Double-blind, Phase 3, Placebo-controlled, Multicentre Trial." Lancet (London, England), vol. 396, no. 10252, 2020, p. 684, https://doi.org/10.1016/S0140-6736(20)31541-5.